Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* PD greater than 3 years~* Stable dose L-dopa but symptoms not adequately controlled and have off time~* Able and willing to complete diary on specific days~Exclusion Criteria:~* Previous use of rotigotine or Neupro~* Atypical Parkinson's syndrome~* Pallidotomy~* Thalamotomy~* Deep brain stimulation~* Fetal tissue transplant~* Dementia~* Psychosis~* Hallucinations~* Epilepsy~* Renal or hepatic dysfunction~* Clinically relevant cardiac dysfunction~* Symptomatic orthostatic hypotension~* Skin sensitivity to adhesives or unresolved contact dermatitis~* History of chronic alcohol or drug abuse~* Pregnant or of child-bearing potential~* Impulse control disorder

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine 2 mg/24 hr (Type: EXPERIMENTAL): None
- Rotigotine 4 mg/24 hr (Type: EXPERIMENTAL): None
- Rotigotine 6 mg/24 hr (Type: EXPERIMENTAL): None
- Rotigotine 8 mg/24 hr (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).